SCHEMBL3892387

SCHEMBL3892387

C[N+](C)(C)c1ccc(C(N)=O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 9/20 0.50
CA2 P00918 3/20 0.50
PARP4 Q9UKK3 2/20 0.50
PARP1 P09874 2/20 0.50
CA1 P00915 2/20 0.50
PARP2 Q9UGN5 1/20 0.50
PARP15 Q460N3 2/20 0.48
ALDH1A1 P00352 2/20 0.48
KMT2A Q03164 1/20 0.48
PARP14 Q460N5 1/20 0.48
PARP16 Q8N5Y8 1/20 0.48
PARP11 Q9NR21 1/20 0.48
TSHR P16473 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
POLB P06746 1/20 0.48
CYP3A4 P08684 1/20 0.48
MAPT P10636 1/20 0.48
CYP2C19 P33261 1/20 0.48
RECQL P46063 1/20 0.48
BLM P54132 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Terephthalamide SCHEMBL23774 0.79 PARP1 (0.71) PARP10CA2PARP4PARP1CA1
SCHEMBL26401371 0.79 PARP10 (0.44) PARP10CA2PARP4PARP1CA1
SCHEMBL4625627 0.78 MAPT (0.50) ALDH1A1KMT2AL3MBTL1MAPTTDP1
SCHEMBL701728 0.78 TSHR (0.60) CA2CA1ALDH1A1TSHRCA12
SCHEMBL9509579 0.77 CA1 (0.39) CA2CA1ALDH1A1KMT2ATSHR
Iodide SCHEMBL21857931 0.76 TSHR (0.57) CA2CA1ALDH1A1TSHRCA12
SCHEMBL22264917 0.76 ACHE (0.41) ALDH1A1KMT2AACHE
Terephthalamide SCHEMBL7508927 0.76 PARP1 (0.67) PARP10CA2PARP4PARP1CA1
Terephthalamide SCHEMBL11512422 0.76 PARP1 (0.67) PARP10CA2PARP4PARP1CA1
Terephthalamide SCHEMBL1087289 0.76 PARP1 (0.67) PARP10CA2PARP4PARP1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572459-B2 Prevention infections in humans, animals STARPHARMA PTY LTD. (AU) 2009-08-11 US disclosed
EP-1113806-B1 ANIONIC OR CATIONIC DENDRIMER ANTIMICROBIAL OR ANTIPARASITIC COMPOSITIONS STARPHARMA PTY LTD (AU) 2007-09-05 EP disclosed
EP-0765357-B9 ANTIVIRAL DENDRIMERS STARPHARMA PTY LTD (AU) 2006-08-16 EP disclosed
EP-0927217-B1 ANGIOGENIC INHIBITORY COMPOUNDS STARPHARMA PTY LTD (AU) 2006-05-03 EP disclosed
EP-0765357-B8 ANTIVIRAL DENDRIMERS STARPHARMA PTY LTD (AU) 2006-03-08 EP disclosed
EP-0765357-B1 ANTIVIRAL DENDRIMERS BIOMOLECULAR RES INST LTD (AU) 2005-12-14 EP disclosed
EP-1113805-A4 INHIBITION OF TOXIC MATERIALS OR SUBSTANCES USING DENDRIMERS STARPHARMA LTD (AU) 2004-05-19 EP disclosed
US-20030129158-A1 Anionic or cationic dendrimer antimicrobial or antiparasitic compositions STARPHARMA LIMITED 2003-07-10 US disclosed
EP-1113806-A4 ANIONIC OR CATIONIC DENDRIMER ANTIMICROBIAL OR ANTIPARASITIC COMPOSITIONS STARPHARMA LTD (AU) 2003-06-25 EP disclosed
EP-0927217-A4 ANGIOGENIC INHIBITORY COMPOUNDS BIOMOLECULAR RES INST LTD (AU) 2003-04-23 EP disclosed
CN-1066726-C Pyrrole derivatives HOFFMANN LA ROCHE (CH) 2001-06-06 CN disclosed
US-6190650-B1 FOR PROPHYLAXIS AND THERAPY OF VIRAL DISEASES IN HUMANS AND ANIMALS BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) 2001-02-20 US disclosed
WO-2000015240-A1 ANIONIC OR CATIONIC DENDRIMER ANTIMICROBIAL OR ANTIPARASITIC COMPOSITIONS STARPHARMA LIMITED (AU) 2000-03-23 WO disclosed
WO-2000015239-A1 INHIBITION OF TOXIC MATERIALS OR SUBSTANCES USING DENDRIMERS STARPHARMA LIMITED (AU) 2000-03-23 WO disclosed
EP-0927217-A1 ANGIOGENIC INHIBITORY COMPOUNDS BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) 1999-07-07 EP disclosed
WO-1998003573-A1 ANGIOGENIC INHIBITORY COMPOUNDS BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) 1998-01-29 WO disclosed
EP-0765357-A4 ANTIVIRAL DENDRIMERS BIOMOLECULAR RES INST LTD (AU) 1997-07-30 EP disclosed
EP-0765357-A1 ANTIVIRAL DENDRIMERS BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) 1997-04-02 EP disclosed
CN-1132206-A Pyrrole derivatives HOFFMANN LA ROCHE (CH) 1996-10-02 CN disclosed
WO-1995034595-A1 ANTIVIRAL DENDRIMERS BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) 1995-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030129158-A1 Anionic or cationic dendrimer antimicrobial or antiparasitic compositions FUT6, B3GNT2, SIGLEC7 PARP10 1170/4885CA2 1974/4885PARP4 2470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.